Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1124 participants
OBSERVATIONAL
2016-04-30
2018-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The initial study record (posted on ClinicalTrials.gov) included a clinical sub-study designed to estimate population level differences in the biomarkers of exposure and clinical risk endpoints among IQOS users, CC smokers and never-smokers. However, due to low recruitment and retention of subjects, the clinical sub-study was terminated in May 2017, and for the same reasons the main study was terminated in March 2018. The study protocol was updated to remove the clinical sub-study objectives. The study initially included 18 outcome measures. Due to study termination leading to a shortened follow-up period and a smaller sample size, only 7 of these outcome measures could be assessed and the other outcome measures planned were either unattainable or uninformative.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity
NCT03887117
Real-Life Passive Exposure Assessment of IQOS
NCT03550989
Acute Effects of a Heat-not-burn Tobacco Product on Pulmonary Function
NCT03889990
The Effects of IQOS Use on Cigarette Smoking Behaviors
NCT05076708
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
NCT03837704
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For IQOS users, the date of initiation of IQOS use was the trigger for all study assessments in the study. However the process was different for CC smokers for whom assessment timing was based on the date of enrollment. IQOS users were enrolled into the study at least two months after initiating use of IQOS (to ensure adoption of IQOS), but less than 12 months after initiating use of IQOS. The study assessments started at the next appropriate study time point after enrollment. Participants were recruited from consumer databases and/or through advertisement. Responses from all eligible participants in the study were collected online using computer assisted self-interviews (CASIs). The questionnaires included demographic information, tobacco use questionnaire including detailed product use and intention to stop tobacco- and nicotine-containing product use, lifestyle assessments, social-economic status, risk perception, nicotine dependence, urge to smoke, as well as self-reported health outcomes. IQOS users were also administered the Modified Cigarette Evaluation Questionnaire, and Self-Reported Changes Questionnaire. The CASIs were administered at the enrollment and quarterly for the first 18 months (at Months 3, 6, 9, 12, 15 and 18).
The study initially was planned to recruit 2,000 IQOS users and 2,000 cigarette (CC) smokers in 4 annual waves (500 IQOS users and 500 CC smokers per wave) and to be followed up to a maximum of 60 months. The first wave of recruitment competed in March 2017. During wave 2 recruitment the study was terminated. A total of 599 IQOS users and 525 CC smokers were enrolled. There was 1 reported protocol deviation in IQOS users, the participant had been using IQOS for 15 months. Due to study termination, only data collected for wave 1 was analyzed.
As this study was observational by design and was conducted in a post-market setting, adverse event (AE) reporting followed the Sponsor's established post-market Safety Surveillance Procedures for spontaneously reported events. IQOS users were reminded of the product quality complaints (including AEs) hotline that is available for all IQOS consumers in Japan.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IQOS Users
The criteria defining an "IQOS user" are listed in the section "Eligibility".
No interventions assigned to this group
Cigarette (CC) Smokers
The criteria defining a "CC smoker" are listed in the section "Eligibility".
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant is Japanese
* Participant is able to understand the information provided in the Informed Consent form (ICF)
* Signed ICF
* Willing to participate in the study and has access to the internet
* For IQOS users:
* Is currently using IQOS with HeatSticks
* Has used at least 100 HeatSticks with IQOS in their lifetime, and
* Has used IQOS with HeatSticks for 2 months or more
* For CC smokers:
* Is currently using CC
* Is not currently using IQOS with HeatSticks, and
* Has used at least 100 CC in their lifetime
Exclusion Criteria
* Employed by the Sponsor, CRO or Clinical Site
* For IQOS users:
* More than 12 months of IQOS use
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kunihiko Uwatoko, MD
Role: PRINCIPAL_INVESTIGATOR
Uwatoko Clinic
Pierpaolo Magnani
Role: STUDY_CHAIR
Philip Morris Products S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uwatoko Clinic
Ōzone, Nagoya, Japan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P1-PMC-01-JP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.